Is Novo Nordisk Now Attractive After a 48.8% Slide and DCF Reassessment? [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Despite its long term 56.8% gain over five years, the stock has fallen 48.8% over the last year and is down 51.5% year to date, which means expectations and risk perception have clearly been reset. Recent headlines have focused on shifting sentiment around weight loss and diabetes treatments, as investors reassess how sustainable Novo Nordisk's growth runway really is. At the same time, regulatory scrutiny and competitive pressure from rival drug developers have added extra volatility to the share price. Right now, Novo Nordisk scores a 5/6 on our valuation checks, suggesting it looks undervalued on most metrics, and next we will unpack what those different valuation approaches say, before finishing with a more holistic way to think about what the stock is truly worth. Find out why Novo Nordisk's -48.8% return over the last year is lagging behind its peers. A Discounted Cash Flow (DCF) model estimates what a company is worth today by projecting the cash it can generate in the
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lilly vs Novo Nordisk. Why 2026 Could Redefine the Obesity Drug Market [Yahoo! Finance]Yahoo! Finance
- American Heart Association (AHA) Scientific Sessions Highlights Report 2025: Market Opportunities Lie in Novel Therapeutics Like Semaglutide, VK2735, SHR-1918, BacNav, and Satralizumab [Yahoo! Finance]Yahoo! Finance
- Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? [Yahoo! Finance]Yahoo! Finance
- While the price of 15 prescription drugs is set to drop, only 5.3M Americans will benefit. Here's what you need to know [Yahoo! Finance]Yahoo! Finance
- ?Novo Nordisk (NVO) Receives Positive Opinion For Wegovy By European Medicines Agency [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website